Skip to content
Clinical Trials – home
Therapeutic area

Vascular disorders – page 23

  • 846 clinical trials
  • 351 recruiting
  • 382 conditions
  • 28 countries

Conditions in this area

382 conditions with trials, the busiest first

Clinical trials in Vascular disorders

846 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

846 clinical trials

Study on Fluasterone for Managing High Blood Sugar in Adults with Cushing's Syndrome

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Fluasterone
  • Sponsor:Sterotherapeutics LLC

Study on the Effectiveness and Safety of NS-229 for Patients with Eosinophilic Granulomatosis with Polyangiitis

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Methyl-(1-{[6-{[(1S)-1-Cyclopropylethyl]Amino}-2-(Pyrazolo[5,1-B][1,3]Thiazol-7-Yl)-Pyrimidin-4-Yl]Carbonyl}Piperidin-4-Yl)Carbamate-Mono(4-Methylbenzenesulfonate) Monohydrate
  • Sponsor:Ns Pharma Inc.

Pulmonary embolism+7

Recruiting

Study on Rosuvastatin for Reducing Blood Clots in Patients with Deep Vein Thrombosis or Pulmonary Embolism

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Rosuvastatin Calcium
  • Sponsor:Centre Hospitalier Regional Et Universitaire De Brest

Study on the Effectiveness of Clopidogrel, Prasugrel, and Ticagrelor in Patients with Coronary Acute Syndrome Using VerifyNow Device

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Clopidogrel
  • Sponsor:Fundacion Epic

Migraine

Recruiting

Long-term safety study of eptinezumab given by intravenous infusion for children and adolescents aged 6-17 years with chronic or episodic migraine

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Eptinezumab
  • Sponsor:H. Lundbeck A/S

Study on Vagus Nerve Stimulation and Sodium Oxybate for Patients with Cerebral Amyloid Angiopathy

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Oxybate
  • Sponsor:Leiden University Medical Center

Study on the Effects of Empagliflozin for Patients with Cardiogenic Shock

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Empagliflozin
  • Sponsor:CHRU De Nancy

Embolism venous

Recruiting

Study on Apixaban for Preventing Blood Clots in Patients Undergoing Abdominal, Gynecologic, and Urologic Surgery

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:HUS-Yhtymae

Sepsis+1

Recruiting

Study Comparing Meropenem and Piperacillin/Tazobactam for Adults with Sepsis

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Linezolid
  • Sponsor:Rigshospitalet

Study on Bosentan for Treating Coronary Artery Spasm in Patients with Ongoing Angina Symptoms

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Bosentan
  • Sponsor:Stichting Radboud universitair medisch centrum

Study on Propofol and Remifentanil for Patients with Heart Disease Undergoing Cardiac Anesthesia with Cardiopulmonary Bypass

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Propofol
  • Sponsor:Medical University Of Vienna

Study on Cangrelor and Bivalirudin for Patients with Heart Attack-Related Cardiogenic Shock or Cardiac Arrest on VA-ECMO Support

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cangrelor Tetrasodium
  • Sponsor:Ospedale San Raffaele S.r.l.

Substances studied in this area

The therapies tested most often in Vascular disorders trials.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.